You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • Correction: The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial

Article Text

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction: The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial

https://doi.org/10.1136/bmjopen-2018-026590corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Ejiri K, Miyoshi T, Nakamura K, et al. The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial. BMJ Open 2019;9:e026590. doi: 10.1136/bmjopen-2018-026590.

    This article was previously published with an error.

    Under ‘Finding’ section, the authors have stated, “This study is funded by Novartis Pharmaceuticals (Basel, Switzerland).”

    The correct sentence is as follows:

    “This study is funded by Novartis Pharma K. K.”

    Linked Articles